JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1
Understanding the disease burden of polycythaemia vera and the challenges of disease management
Polycythaemia vera (PV) is a myeloproliferative disorder that causes overproduction of red blood cells and is characterised by high symptom burden, risk of thrombotic events and disease transformation, and shortened life expectancy.2,3
This content is intended for UK healthcare professionals only and has been created and funded by Novartis Pharmaceuticals UK Ltd.
Overview
Take these short modules to learn about the range of symptoms experienced by patients with PV, the diagnostic process, the signs of disease progression and the treatment options available.
Module 1
The symptom burden, complications and prognosis of polycythaemia vera
In this module you will gain an increased awareness of the diagnostic criteria for PV as well as the range of symptoms experienced by patients and the risk of disease progression.
Module 2
Timely management of polycythaemia vera: considerations and pitfalls
Complete this module to learn more about the different treatment options available for PV and their limitations, and understand the risks associated with insufficient control of PV.
Module 3
The treatment landscape for polycythaemia vera
Increase your knowledge on first-, second- and later-line treatment options for PV, view risk: benefit considerations and read BSH guideline recommendations for high-risk patients.
By clicking on the links above, you will be leaving the Novartis UK HCP portal.
BSH, British Society for Haematology; PV, polycythaemia vera.
References
JAKAVI® (ruxolitinib) Summary of Product Characteristics.
Teeri A, et al. Leukemia 2021;35(12):3339–3351.
Harrison CN, et al. Ann Hematol 2017;96(10):1653–1665.
UK | November 2024 | FA-11208708
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.